Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

2. Verisk Analytics

8.4% sales growth and 28.74% return on equity

Verisk Analytics, Inc. provides data analytics solutions in the United States and internationally.

Verisk Analytics’s sales growth this year is expected to be 6.9% and 6.5% for next year.

Year-on-year quarterly revenue growth grew by 5.4%, now sitting on 2.78B for the twelve trailing months.

Verisk Analytics’s sales growth for the next quarter is 8.4%. The company’s growth estimates for the current quarter and the next is 6.8% and 3.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.74%.

Volatility

Verisk Analytics’s last day, last week, and last month’s current volatility was 0.21%, 0.53%, and 0.68%, respectively.

Verisk Analytics’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.92% (day), 1.21% (last week), and 1.44% (last month), respectively.

Verisk Analytics’s Stock Yearly Top and Bottom Value

Verisk Analytics’s stock is valued at $188.20 at 08:22 EST, way below its 52-week high of $210.66 and way above its 52-week low of $151.18.

Verisk Analytics’s Moving Average

Verisk Analytics’s value is higher than its 50-day moving average of $180.62 and below its 200-day moving average of $188.47.

3. Addus HomeCare Corporation

18.3% sales growth and 6.56% return on equity

Addus HomeCare Corporation provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States.

Addus HomeCare Corporation’s sales growth this year is expected to be 13.9% and 7.3% for next year.

Year-on-year quarterly revenue growth grew by 7.9%, now sitting on 779.86M for the twelve trailing months.

Addus HomeCare Corporation’s sales growth for the next quarter is 18.3%. The company’s growth estimates for the ongoing quarter and the next is 20.5% and 19.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.56%.

Volatility

Addus HomeCare Corporation’s last day, last week, and last month’s current volatility was 6.31%, 2.75%, and 1.72%, respectively.

Addus HomeCare Corporation’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 10.55% (day), 5.01% (last week), and 3.03% (last month), respectively.

Addus HomeCare Corporation’s Stock Yearly Top and Bottom Value

Addus HomeCare Corporation’s stock is valued at $92.87 at 08:22 EST, way below its 52-week high of $129.01 and way higher than its 52-week low of $77.62.

Addus HomeCare Corporation’s Moving Average

Addus HomeCare Corporation’s worth is way under its 50-day moving average of $106.53 and way under its 200-day moving average of $109.00.

4. Baxter International

13.2% sales growth and 13.28% return on equity

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products.

Baxter International’s sales growth this year is expected to be 8.2% and 5.3% for next year.

Year-on-year quarterly revenue growth grew by 5.1%, now sitting on 11.82B for the twelve trailing months.

Baxter International’s sales growth for the next quarter is 13.2%. The company’s growth estimates for the ongoing quarter and the next is 18.8% and 13.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.28%.

Volatility

Baxter International’s last day, last week, and last month’s current volatility was 0.40%, 0.77%, and 0.61%, respectively.

Baxter International’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.24% (day), 1.79% (last week), and 1.43% (last month), respectively.

Baxter International’s Stock Yearly Top and Bottom Value

Baxter International’s stock is valued at $86.54 at 08:22 EST, below its 52-week high of $95.19 and way higher than its 52-week low of $74.79.

Baxter International’s Moving Average

Baxter International’s value is above its 50-day moving average of $79.78 and above its 200-day moving average of $79.38.

5. QUALCOMM

30.4% sales growth and 153.25% return on equity

QUALCOMM Incorporated designs, develops, manufactures, and markets digital communication products worldwide.

QUALCOMM’s sales growth this year is expected to be 48.6% and 8.6% for next year.

Year-on-year quarterly revenue growth grew by 52.1%, now sitting on 29.41B for the twelve trailing months.

QUALCOMM’s sales growth is a negative 0% for the current quarter and 30.4% for the next. The company’s growth estimates for the current quarter and the next is 94.2% and 40.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 153.25%.

Volatility

QUALCOMM’s last day, last week, and last month’s current volatility was 0.40%, 1.53%, and 1.62%, respectively.

QUALCOMM’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.74% (day), 2.29% (last week), and 2.23% (last month), respectively.

QUALCOMM’s Stock Yearly Top and Bottom Value

QUALCOMM’s stock is valued at $136.00 at 08:22 EST, way below its 52-week high of $167.94 and way higher than its 52-week low of $70.00.

QUALCOMM’s Moving Average

QUALCOMM’s value is above its 50-day moving average of $134.05 and below its 200-day moving average of $139.84.

6. The Joint Corp.

40.3% sales growth and 99.48% return on equity

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States.

The Joint Corp.’s sales growth this year is expected to be 27.1% and 25.6% for next year.

Year-on-year quarterly revenue growth grew by 22.8%, now sitting on 58.68M for the twelve trailing months.

The Joint Corp.’s sales growth for the next quarter is 40.3%. The company’s growth estimates for the ongoing quarter and the next is 100% and negative -36.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 99.48%.

Volatility

The Joint Corp.’s last day, last week, and last month’s current volatility was 11.06%, 3.23%, and 3.09%, respectively.

The Joint Corp.’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 12.23% (day), 6.22% (last week), and 5.65% (last month), respectively.

The Joint Corp.’s Stock Yearly Top and Bottom Value

The Joint Corp.’s stock is valued at $50.81 at 08:22 EST, way below its 52-week high of $58.63 and way above its 52-week low of $10.91.

The Joint Corp.’s Moving Average

The Joint Corp.’s value is above its 50-day moving average of $49.98 and way above its 200-day moving average of $34.95.

7. World Wrestling Entertainment

13.2% sales growth and 45.33% return on equity

World Wrestling Entertainment, Inc., an integrated media and entertainment company, engages in the sports entertainment business in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America.

World Wrestling Entertainment’s sales growth this year is expected to be 11.2% and 14.7% for next year.

Year-on-year quarterly revenue growth declined by 9.4%, now sitting on 946.72M for the twelve trailing months.

World Wrestling Entertainment’s sales growth for the next quarter is 13.2%. The company’s growth estimates for the ongoing quarter and the next is a negative 55.8% and negative -33.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 45.33%.

Volatility

World Wrestling Entertainment’s last day, last week, and last month’s current volatility was 2.85%, 1.18%, and 1.29%, respectively.

World Wrestling Entertainment’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.62% (day), 2.18% (last week), and 2.58% (last month), respectively.

World Wrestling Entertainment’s Stock Yearly Top and Bottom Value

World Wrestling Entertainment’s stock is valued at $54.21 at 08:22 EST, way under its 52-week high of $61.32 and way above its 52-week low of $35.44.

World Wrestling Entertainment’s Moving Average

World Wrestling Entertainment’s value is under its 50-day moving average of $56.11 and way higher than its 200-day moving average of $49.27.

8. Halozyme Therapeutics

39.8% sales growth and 106.32% return on equity

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally.

Halozyme Therapeutics’s sales growth this year is expected to be 45.7% and 50.1% for next year.

Year-on-year quarterly revenue growth grew by 126.8%, now sitting on 267.59M for the twelve trailing months.

Halozyme Therapeutics’s sales growth for the next quarter is 39.8%. The company’s growth estimates for the ongoing quarter and the next is 900% and 94.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 106.32%.

Volatility

Halozyme Therapeutics’s last day, last week, and last month’s current volatility was 0.25%, 1.48%, and 1.48%, respectively.

Halozyme Therapeutics’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.44% (day), 2.71% (last week), and 3.24% (last month), respectively.

Halozyme Therapeutics’s Stock Yearly Top and Bottom Value

Halozyme Therapeutics’s stock is valued at $47.69 at 08:22 EST, way below its 52-week high of $56.40 and way above its 52-week low of $22.11.

Halozyme Therapeutics’s Moving Average

Halozyme Therapeutics’s value is higher than its 50-day moving average of $45.42 and way higher than its 200-day moving average of $42.90.

LEAVE A REPLY

Please enter your comment!
Please enter your name here